<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postoperative peritoneal adhesions in adults and their prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postoperative peritoneal adhesions in adults and their prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Postoperative peritoneal adhesions in adults and their prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan H DeCherney, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Senthil Kumar, MS, FRCS (Ed), FRCS (Gen Surg), CCT (UK)</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amalia Cochran, MD, FACS, FCCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tommaso Falcone, MD, FRCSC, FACOG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Postoperative peritoneal adhesions have important consequences to patients, surgeons, and the health system. The adhesions that form in the abdomen following abdominal or pelvic surgery are a normal response to injury of the peritoneal surfaces during surgery, and although adhesions have some beneficial effects, they also cause significant morbidity, including adhesive small bowel obstruction, female infertility, chronic abdominal pain, and increased difficulty with subsequent surgery [<a href="#rid1">1,2</a>]. These issues have refocused attention on our understanding of adhesions, their clinical consequences, and methods of prevention. A number of animal studies and human interventional trials have evaluated a variety of techniques and materials designed to reduce and prevent postsurgical adhesions. Only a handful of agents have been proven safe and effective in humans, and fewer have an evidence base that justifies routine use. </p><p>The epidemiology, pathogenesis, approach, and importance of preventing postoperative peritoneal adhesions in adults are reviewed here. The diagnosis and management of small bowel obstruction and infertility are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8037.html" rel="external">"Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults"</a> and  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE AND BURDEN</span><span class="headingEndMark"> — </span>Postoperative adhesions cause significant morbidity, including bowel obstruction, female infertility, and chronic abdominal and pelvic pain [<a href="#rid3">3-6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Intestinal obstruction – Adhesions are the most common cause of intestinal obstruction in Western countries [<a href="#rid7">7-9</a>]. The incidence varies widely with the nature of the index surgery and the duration of follow-up [<a href="#rid7">7,10-14</a>]. The incidence of small bowel obstruction resulting from postoperative adhesions increases with each subsequent procedure performed in the management of bowel obstruction. In one national study, 5.7 percent of 21,347 readmissions were classified as relating directly to adhesions, and 3.8 percent required operation [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infertility – Infertility in women can result from pelvic adhesions, which can alter pelvic anatomy and interfere with ovum capture and transport, or from tubal or intrauterine adhesions that hinder sperm transport or embryo implantation. Whereas pelvic peritoneal adhesions and tubal abnormalities are each responsible for approximately 10 percent of cases of female infertility, intrauterine adhesions are a relatively rare cause of infertility. (See  <a class="medical medical_review" href="/d/html/7396.html" rel="external">"Overview of infertility", section on 'Causes of infertility'</a> and  <a class="medical medical_review" href="/d/html/3285.html" rel="external">"Intrauterine adhesions: Clinical manifestation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic abdominal pain – The relationship between adhesions and chronic abdominal or pelvic pain is poorly defined. However, there is some evidence indicating that dense adhesions can limit organ mobility, which may cause visceral pain [<a href="#rid2">2,15,16</a>]. (See  <a class="medical medical_review" href="/d/html/5435.html" rel="external">"Chronic pelvic pain in adult females: Treatment", section on 'When to perform additional surgical procedures aimed to reduce pain'</a>.)</p><p></p><p>Adhesions, which are found in up to 95 percent of patients who have subsequent surgery, can impose technical difficulties and increase risk for complications, which may include [<a href="#rid17">17-19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Difficult abdominal access related to loss of tissue planes or distorted anatomy</p><p class="bulletIndent1"><span class="glyph">●</span>Inability to perform laparoscopic surgery, continuous ambulatory dialysis, or other intra-abdominal drug delivery</p><p class="bulletIndent1"><span class="glyph">●</span>Inadvertent injury to the small bowel, bladder, or ureters </p><p class="bulletIndent1"><span class="glyph">●</span>Increased duration of surgery and prolonged anesthesia </p><p class="bulletIndent1"><span class="glyph">●</span>Increased blood loss</p><p></p><p>Nearly 1 percent of all general surgical admissions and 3 percent of all laparotomies relate directly to adhesions [<a href="#rid20">20</a>], which increases the burden of care (economic, manpower, logistics). Furthermore:</p><p class="bulletIndent1"><span class="glyph">●</span>Complications related to or resulting from postoperative adhesions increase the surgical workload and hospital utilization and tax other health care resources, resulting in a significant economic burden; the overall estimated annual costs of managing adhesion-related complications exceed $2 billion in the United States [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adhesions increase the risk for medical malpractice claims arising from abdominal and pelvic surgery [<a href="#rid4">4,22,23</a>]. Data from the medical defense union in the United Kingdom identified 77 claims related to adhesions over a six-year interval [<a href="#rid22">22</a>]. Allegations included a failure to warn of the risk during the consent process, visceral injuries that occurred during laparoscopy or laparotomy, failure to use specific measures to prevent adhesions, failure to diagnose or delays in diagnosis of complications, and chronic pain and infertility. </p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>At the molecular level, adhesion formation involves a complex interaction of cytokines, growth factors, cell adhesion molecules, neuropeptides, and numerous other factors secreted by cells in or near the area of trauma [<a href="#rid24">24,25</a>]. The early balance between fibrin deposition and degradation (ie, fibrinolysis) appears to be a critical factor in the pathogenesis of adhesions [<a href="#rid26">26-30</a>]. Peritoneal healing differs from wound healing in that it heals as a surface rather than from edge to edge (like skin). Healing involves a uniform, relatively rapid reepithelialization, regardless of the size of the injury. </p><p>Injury to peritoneal surfaces induces a repair response, which consists of an inflammatory reaction involving cellular elements and also tissue and coagulation factors [<a href="#rid29">29,31</a>]. The inflammatory response results in fibrin deposition at the site of injury within three hours after tissue trauma and peaks on postoperative days 4 to 5. Postsurgical peritoneal repair begins with coagulation, which triggers the release of a variety of chemical messengers that mediate a cascade of events. Some of the principal cellular elements involved include leukocytes (polymorphonuclear neutrophils and macrophages) and mesothelial cells. Macrophages, which exhibit increased phagocytic, respiratory burst, and secretory activities, comprise the majority of the local leukocyte population five days after injury. Macrophages also recruit new mesothelial cells onto the surface of the injury, which first aggregate to form small islands across the injured area and then proliferate into sheets of cells that eventually reepithelialize the entire surface, usually by five to seven days after surgical injury. </p><p>The progenitor to adhesions is the fibrin gel matrix, which develops in several steps, including the formation and degradation of fibrin polymer and its interaction with fibronectin and a series of amino acids. Protective fibrinolytic enzyme systems in the peritoneal mesothelium, such as the tissue plasminogen activator (tPA) system, can remove the fibrin gel matrix. The pivotal events that determine the path of healing are the opposition of two damaged surfaces and the extent of fibrinolysis. If complete fibrinolysis and resorption of degradation products occurs, reepithelialization will result in a smooth tissue surface, but if that process is disturbed and fibrinolysis does not occur, connective tissue scar and adhesions develop from the ingrowth of fibroblasts, capillaries, and nerves. Surgery diminishes fibrinolytic activity dramatically by increasing levels of plasminogen activator inhibitors and reducing tissue oxygenation [<a href="#rid30">30,31</a>]. Fibrinolysis also can be impaired by thermal injury, desiccation, ischemia, foreign bodies, blood, bacteria, and some drugs; genetic polymorphisms also may play a role in the host's inflammatory and healing response.</p><p class="headingAnchor" id="H295552710"><span class="h1">CLINICAL PRESENTATIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Most adhesions are clinically silent. More than 75 percent of patients with symptomatic adhesions have a history of prior surgery, and the remainder have a history of an intra-abdominal or pelvic inflammatory process. When symptoms occur, adhesions may manifest as intestinal obstruction, chronic pain, and, in women, as infertility. The risk factors and clinical features for each of these are described in the linked topics.</p><p class="bulletIndent1"><span class="glyph">●</span>Adhesions are the most common cause of intestinal obstruction in Western countries and should be suspected in any patient with a history of prior abdominal or pelvic surgery who presents with signs and symptoms of obstruction. The presentation can be acute or subacute. (See  <a class="medical medical_review" href="/d/html/8037.html" rel="external">"Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults", section on 'Etiologies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic abdominal pain, chronic pelvic pain, and/or dyspareunia [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/6862.html" rel="external">"Evaluation of the adult with abdominal pain"</a> and  <a class="medical medical_review" href="/d/html/5490.html" rel="external">"Chronic pelvic pain in nonpregnant adult females: Causes"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infertility. (See  <a class="medical medical_review" href="/d/html/7396.html" rel="external">"Overview of infertility"</a> and  <a class="medical medical_review" href="/d/html/5408.html" rel="external">"Female infertility: Causes"</a> and  <a class="medical medical_review" href="/d/html/5445.html" rel="external">"Female infertility: Evaluation"</a>.)</p><p></p><p>A diagnosis of adhesions is often based on initial clinical suspicion in a relevant context, which may then be confirmed by direct examination of the abdomen or pelvis via laparoscopy or laparotomy or with indirect methods, such as imaging, which is less accurate and may include ultrasound (demonstrating reduced visceral sliding) or magnetic resonance of the abdomen. Computed tomography (CT) of the abdomen (with oral contrast) and gastrointestinal follow-through studies are less useful in the diagnosis of adhesions but can play a role in the management of patients with suspected small bowel obstruction relating to adhesions. (See  <a class="medical medical_review" href="/d/html/8037.html" rel="external">"Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H355412688"><span class="h1">INDICATIONS FOR ADHESIOLYSIS</span><span class="headingEndMark"> — </span>The indications for surgical lysis of adhesions depend upon the clinical presentation.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with signs and symptoms of bowel obstruction, abdominal exploration and lysis of adhesions (adhesiolysis) may be needed to manage complications related to obstruction (perforation, ischemia). Adhesiolysis also may be indicated for those with partial obstruction who do not respond to conservative management. (See  <a class="medical medical_review" href="/d/html/89300.html" rel="external">"Management of small bowel obstruction in adults", section on 'Failure of nonoperative management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment of infertility and recurrent pregnancy loss, lysis of pelvic adhesions or of intrauterine adhesions may improve fecundity and decrease risk for pregnancy loss. (See  <a class="medical medical_review" href="/d/html/5448.html" rel="external">"Female infertility: Treatments"</a> and  <a class="medical medical_review" href="/d/html/3285.html" rel="external">"Intrauterine adhesions: Clinical manifestation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Performing adhesiolysis for pain relief can be effective in certain subsets of patients [<a href="#rid2">2</a>]. Unfortunately, even after lysis, adhesions often reform. (See  <a class="medical medical_review" href="/d/html/89300.html" rel="external">"Management of small bowel obstruction in adults"</a> and  <a class="medical medical_review" href="/d/html/5409.html" rel="external">"Female sexual pain: Differential diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">MEASURES FOR PREVENTING PERITONEAL ADHESIONS</span></p><p class="headingAnchor" id="H10175862"><span class="h2">Fundamentals</span><span class="headingEndMark"> — </span>Methods for preventing adhesions are directed at the mechanisms of adhesion formation. Preventive measures may (see <a class="local">'Pathogenesis'</a> above): </p><p class="bulletIndent1"><span class="glyph">●</span>Minimize injury</p><p class="bulletIndent1"><span class="glyph">●</span>Introduce a barrier between injured surfaces</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent coagulation of the serous exudate</p><p class="bulletIndent1"><span class="glyph">●</span>Remove or dissolve the deposited fibrin</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibit the fibroblastic response to the tissue injury</p><p class="bulletIndent1"><span class="glyph">●</span>Involve recombinant tissue plasminogen activator and novel fibrinolytics</p><p class="bulletIndent1"><span class="glyph">●</span>Minimize postoperative infection risk</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Methods for preventing adhesions can be classified broadly as technical measures; physical barriers, which may be solid or liquid; and pharmacologic therapies [<a href="#rid3">3,25</a>]. Given that no specific pharmacologic therapy has been approved for clinical use in the United States, the discussion below focuses on technical measures and physical barriers [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Technical measures limit or prevent the initial peritoneal injury. (See <a class="local">'Surgical techniques'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Barrier agents act primarily as a physical separation between the fibrin-coated peritoneal surfaces predisposed to adherence. Barrier agents may be solid or liquid materials. (See <a class="local">'Physical barriers'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal bowel motility can help keep physical separation of healing surfaces and maintain relative motion between healing surfaces, which in turn prevent or limit adhesion formation. Measures that promote bowel motility in a postoperative patient are discussed elsewhere. (See <a class="local">'Promotion of bowel motility'</a> below and  <a class="medical medical_review" href="/d/html/15155.html" rel="external">"Measures to prevent prolonged postoperative ileus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologic therapies may be administered locally or systemically and interfere with or modify the peritoneal response to injury. (See <a class="local">'Ineffective and potentially harmful therapies'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Surgical techniques</span></p><p class="headingAnchor" id="H355417227"><span class="h3">Gentle tissue handling</span><span class="headingEndMark"> — </span>Good surgical technique is the first defense against adhesion formation. </p><p>Meticulous hemostasis and gentle, minimal tissue handling are important for limiting the extent of the initial peritoneal injury [<a href="#rid16">16</a>]. Damage to the serosa can be prevented by minimizing trauma, bleeding, and ischemia and by keeping the surgical field moist with frequent irrigation to prevent tissues from drying out. </p><p>Traditional laparotomy sponges can be abrasive and should be avoided. Many pelvic surgeons place these sponges in sterile plastic bags, thus preventing the braided cloth from touching the peritoneum when packing is required. </p><p>Removing the talc or starch from gloves before entering the peritoneal cavity is a simple, but often neglected, measure that eliminates a source of irritation that predisposes to adhesion formation. The introduction of potentially reactive foreign bodies (eg, excess suture material, lint, talc) should be minimized to reduce the number of nidi for fibrin deposition. Fine, nonreactive suture material should be used wherever possible; silk sutures, which are fibrogenic, should be avoided in the abdomen. </p><p>The incidence of adhesions is similar regardless of whether the peritoneum is reapproximated after laparotomy [<a href="#rid13">13,34,35</a>]. Although closing the parietal peritoneum is usually unnecessary, when circumstances require, fine, absorbable suture should be used. Suture materials like polyglactin stimulate little tissue reactivity and are thus preferred over more reactive materials such as chromic catgut sutures or silk.</p><p class="headingAnchor" id="H90682180"><span class="h3">Laparoscopic surgery</span><span class="headingEndMark"> — </span>Laparoscopy offers certain advantages over open abdominal surgery with respect to adhesion formation. The abdominal incisions are small, and there is less handling of tissue and exposure to foreign bodies, all of which may help to decrease tissue trauma, compared with laparotomy, and thus reduce the risk for adhesion formation, especially to the abdominal wall [<a href="#rid36">36-38</a>]. </p><p>Laparoscopic surgery certainly does not guarantee the prevention of adhesions [<a href="#rid39">39</a>]; longer durations of surgery and high insufflation pressures can even increase the risk for adhesion formation [<a href="#rid40">40</a>]. In one study (SCAR), the Scottish National Health Service Medical Record Linkage Database was used to select a cohort of 8849 women who had open gynecologic surgery in 1986, and all readmissions in the subsequent 10 years were reviewed for potential adhesion-related disease [<a href="#rid10">10-12</a>]. The overall rate of readmission directly related to adhesions was 2.9/100 initial operations. When laparoscopic sterilization procedures were excluded, the risk for adhesion-related readmission was comparable for open and laparoscopic gynecologic surgery [<a href="#rid11">11</a>].</p><p>Since the publication of the original SCAR study in 1999 [<a href="#rid12">12</a>], the field of laparoscopic surgery has advanced from mostly diagnostic procedures to complex resectional procedures. In an updated study using the same database but in a more contemporary time frame (2009 to 2011), over 50,000 patients underwent open abdominal or pelvic surgery while over 21,000 patients underwent laparoscopic surgery [<a href="#rid41">41</a>]. At five years, compared with open surgery, the laparoscopic approach was associated with a lower incidence of readmissions directly related to adhesions (1.7 versus 4.3 percent; p&lt;0.0001) and a lower incidence of readmissions possibly related to adhesions (16 versus 18 percent; p&lt;0.005). Despite these reduced risks, however, laparoscopic surgery is still associated with adhesion formation resulting in readmissions. </p><p class="headingAnchor" id="H7"><span class="h2">Physical barriers</span><span class="headingEndMark"> — </span>Physical barriers include solid materials (absorbable sheets, nonabsorbable prosthetic materials) and viscous fluids introduced into the abdomen. All are aimed at keeping damaged peritoneal surfaces separated during the first five to seven days after surgery until after reepithelialization has occurred. Although barriers do appear to limit the extent of adhesion formation, whether they improve clinically important outcomes by reducing the risks for intestinal obstruction, infertility, and chronic abdominal or pelvic pain is less clear [<a href="#rid1">1,42</a>]. (See <a class="local">'Effectiveness of physical barriers'</a> below.)</p><p>The addition of physical barriers is not without risk or cost. The use of the barriers described below prolongs operative time, which increases hospital costs, which is compounded further by the cost of the product itself, for an estimated total of $400 to $700 per procedure. However, when these barriers accomplish what they are designed to do, the benefit of avoiding future surgery outweighs these issues.</p><p>Concerns that some barrier agents may predispose to an increase in the incidence of septic complications [<a href="#rid43">43-45</a>] have not been proven, but barriers should <strong>not</strong> be used to wrap intestinal anastomoses, because the practice may increase the risk for leak [<a href="#rid46">46,47</a>]. In one multicenter trial, 1791 patients having abdominopelvic surgery (the majority for inflammatory bowel disease) were randomly assigned to receive a hyaluronic acid sheet as an adhesion barrier or no treatment [<a href="#rid47">47</a>]. There was no significant difference between the groups in the incidence of abscess (4 versus 3 percent, respectively) or pulmonary embolism (&lt;1 percent in both groups). However, a subpopulation of patients in whom the adhesion barrier was wrapped around a fresh bowel anastomosis more frequently developed anastomotic leak and leak-related events, such as fistula formation, peritonitis, abscess formation, and sepsis. </p><p>Adhesion barrier use has also been associated with an increase in intraperitoneal or uterine infections after cesarean section [<a href="#rid48">48</a>]. In one case-control study, adhesion barriers were used in 77 percent of 1498 cesarean section cases, and intraperitoneal or uterine infections occurred in 9.9 and 4.3 percent of those with and without adhesion barriers, respectively [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H166926421"><span class="h3">Solid barriers (sheets)</span><span class="headingEndMark"> — </span>Two absorbable membrane sheets are commercially available. One is a sodium hyaluronate-based <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a> sheet (Seprafilm), and the second is an <a class="drug drug_general" data-topicid="10083" href="/d/drug information/10083.html" rel="external">oxidized regenerated cellulose</a> sheet (Interceed). Both appear safe and effective for preventing adhesions between surfaces to which they are applied but are somewhat difficult to handle and do not prevent adhesion formation at other sites within the abdomen. In addition, there is one nonabsorbable solid barrier (expanded polytetrafluoroethylene) that has been found to prevent adhesions in clinical studies. </p><p class="headingAnchor" id="H10"><span class="h4">Hyaluronic acid sheets</span><span class="headingEndMark"> — </span>Hyaluronic acid sheets (hyaluronate <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a>) are transparent, absorbable membranes that last for seven days, during which time they prevent the juxtaposition of traumatized tissues. </p><p>Hyaluronate <a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a> (Seprafilm) is supplied in 5 x 6 inch sheets. The desired shape is cut, and the material is carefully applied with clean instruments over the surgical site. Care should be taken to avoid contacting the viscera and other tissues prior to final placement, and the barrier is best applied with instruments because the membrane can easily stick to gloves and become displaced. The paper backing on the film is then removed carefully, keeping the membrane at the operative site; suturing is unnecessary. The barrier is a brittle film that tends to fracture when bent at sharp angles, making it unsuitable for laparoscopic application.</p><p>A meta-analysis of eight randomized trials of patients undergoing intestinal surgery [<a href="#rid47">47,49-55</a>] demonstrated that treatment with hyaluronic acid sheets reduced intra-abdominal adhesions significantly but did not reduce the incidence of postoperative intestinal obstruction (odds ratio [OR] 0.98, 95% CI 0.78-1.23). Hyaluronic acid sheet use also increased septic complications such as abdominal abscess (OR 1.64, 95% CI 1.06-2.54) and anastomotic leak (OR 2.03, 95% CI 1.18-3.50) [<a href="#rid43">43</a>]. Another meta-analysis of nine trials demonstrated a reduction in the incidence of postoperative small bowel obstruction (pooled risk ratio 0.45, 95% CI 0.34-0.60). The benefit was sustained at both two and five years [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1839993"><span class="h4">Oxidized regenerated cellulose</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10083" href="/d/drug information/10083.html" rel="external">Oxidized regenerated cellulose</a> (ORC) is a commonly employed absorbable adjuvant used for hemostasis. (See  <a class="medical medical_review" href="/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives", section on 'Oxidized regenerated cellulose'</a>.)</p><p>ORC creates a temporary barrier that prevents adhesions when applied to injured tissue. Initial studies using a version of the product with a loose weave (Surgicel) were inconclusive but suggested some benefit. The knit of the ORC barrier was subsequently modified to create the ORC product used currently (Interceed). The material is effective for reducing postsurgical adhesions because it is absorbed over an interval, which presumably allows sufficient time for fibrin-clot dissolution and reepithelialization of the traumatized peritoneum [<a href="#rid57">57</a>]. A systematic review and meta-analysis identified 11 trials using ORC in gynecologic surgery [<a href="#rid38">38,58-67</a>]. The pooled estimate for three trials comparing ORC with no barrier and judged to have a low risk for bias observed that ORC significantly reduced risk of adhesions (relative risk [RR] 0.51, 95% CI 0.31-0.86) [<a href="#rid1">1</a>].</p><p>Interceed is supplied in sheets measuring 1.5 x 2 inches or 3 x 4 inches. The smaller size is appropriate for laparoscopic placement. The barrier is degraded and absorbed within two weeks of application. Application requires several steps:</p><p class="bulletIndent1"><span class="glyph">●</span>The operative site should exhibit normal hemostasis and be free of blood, which reduces the effectiveness of ORC [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excess fluid should be removed from the peritoneal cavity by gentle aspiration after placing the patient in a reverse Trendelenburg position.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Interceed barrier should completely cover the affected area of the operative site and can be moistened gently with sterile irrigant to help maintain its position. Suturing is unnecessary.</p><p></p><p class="headingAnchor" id="H11"><span class="h4">Expanded polytetrafluoroethylene</span><span class="headingEndMark"> — </span>Expanded polytetrafluoroethylene (ePTFE) is a nonabsorbable, flexible prosthetic material used for a variety of surgical reconstructions. The ePTFE is trimmed to overlap the denuded area by 1 cm and sutured into place with nonabsorbable sutures, usually 7-0 or 8-0 nylon or polypropylene. </p><p>A small trial of patients having open myomectomy randomly assigned 28 subjects to application of ePTFE suture over the uterine incision or to no barrier [<a href="#rid69">69</a>]. At second-look laparoscopy, more patients receiving ePTFE were adhesion free compared with untreated controls (55 versus 7 percent).</p><p>Another small trial involving 32 patients compared ePTFE and ORC in pelvic reconstructive surgery by placing ePTFE on one pelvic sidewall and ORC on the other [<a href="#rid70">70</a>]. Among the 29 patients who had second-look laparoscopy, both ORC and ePTFE decreased adhesions, but ePTFE was judged to be more effective (<a class="graphic graphic_figure graphicRef56961" href="/d/graphic/56961.html" rel="external">figure 1</a>). More sidewalls covered with ePTFE had no adhesions (21 versus 7). The ePTFE membrane was removed at laparoscopy in all patients who had a successful second-look procedure. </p><p class="headingAnchor" id="H166926441"><span class="h3">Liquid barriers (instillates)</span></p><p class="headingAnchor" id="H12"><span class="h4">Polyethylene glycol</span><span class="headingEndMark"> — </span>Polyethylene glycol adhesion barrier (Spraygel, Sprayshield) is a synthetic hydrogel that forms within seconds after simultaneous spray of two solutions of polyethylene glycol-based (PEG) liquids onto targeted tissue. Crosslinking between the solutions forms an absorbable, flexible, adherent gel barrier that remains intact for five to seven days before degrading into its components, which are then resorbed and excreted through the kidneys. Spraygel is available in Europe but is not yet approved for use in the United States.</p><p>An early trial comparing PEG with placebo in women undergoing myomectomy observed a greater than 60 percent lower adhesion score in treated patients at time of second-look laparoscopy, with no adverse effects [<a href="#rid71">71</a>]. A later systematic review [<a href="#rid1">1</a>] identified seven trials comparing PEG with placebo [<a href="#rid71">71-76</a>]. Whereas the pooled results of four of these trials did not yield a significant difference in the overall incidence of adhesions, adhesion scores were lower in those receiving PEG. A later trial confirmed the safety profile of Spraygel but also failed to demonstrate the barrier was effective for preventing adhesions [<a href="#rid77">77</a>]. </p><p class="headingAnchor" id="H14"><span class="h4">Icodextrin solution</span><span class="headingEndMark"> — </span>A 4% isosmolar solution of <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> (Adept) is an alpha-1,4 glucose polymer with prolonged peritoneal residence. It is used as an irrigant during surgery (minimum 100 mL/30 minutes) and is the most promising intraoperative instillate for adhesion prevention. It can be used following laparoscopic adhesiolysis and is the only agent approved in the United States for preventing peritoneal adhesions in gynecologic laparoscopy.</p><p>At completion of the procedure, all of the irrigant is removed and 1000 mL of fresh <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> 4% is instilled into the peritoneal cavity and left as a fluid reservoir [<a href="#rid78">78</a>]. The solution is slowly absorbed via the lymphatic system, broken down by amylase, and metabolized to glucose (40 g per liter of instillate) over a period of up to four days, thus acting to separate traumatized tissue surfaces during the period of healing when adhesions would normally form. Adept is contraindicated in patients with known or suspected allergy to cornstarch-based polymers (eg, icodextrin, or with maltose or isomaltose intolerance, or with glycogen storage disease). Icodextrin 4% is also contraindicated in the presence of gross abdominal-pelvic infection. </p><p>A meta-analysis of four trials comparing <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> to no treatment or placebo concluded that icodextrin reduced the incidence of small bowel obstruction (data from a single study, 2 versus 11 percent) but did not reduce adhesion formation or the need for reoperation for adhesive small bowel obstruction (relative risk 0.33, 95% CI 0.03-3.11) [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H15"><span class="h4">Hyaluronic acid solution, gel, and powder</span><span class="headingEndMark"> — </span>Hyaluronic acid is an anionic, nonsulfated glycosaminoglycan distributed in connective tissue [<a href="#rid79">79-81</a>].</p><p>A systematic review identified four trials comparing hyaluronic acid-containing solutions with placebo [<a href="#rid82">82-85</a>] and found no difference in overall mean adhesions scores but also found that the solutions significantly reduced the proportion of women with adhesions or the extent of adhesions at time of second-look laparoscopy (OR 0.31, 95% CI 0.19-0.51) and the number of women with increased adhesion scores (OR 0.28, 95% CI 0.12-0.66) [<a href="#rid80">80</a>]. </p><p>A powder form of hyaluronic acid/<a class="drug drug_general" data-topicid="8844" href="/d/drug information/8844.html" rel="external">carboxymethylcellulose</a> (Sepraspray Adhesion Barrier) has been evaluated in the setting of laparoscopic colorectal resections but was found to produce more adverse events [<a href="#rid86">86</a>]. </p><p class="headingAnchor" id="H14810112"><span class="h3">Promotion of bowel motility</span><span class="headingEndMark"> — </span>As an adjunct to physical separation of healing surfaces, maintenance of relative motion between healing surfaces, mimicking normal peristalsis and mobility, has been proposed to prevent or limit adhesion formation. In humans, impaired postoperative intestinal motility may cause a postoperative ileus, further exacerbated by postoperative pain management with opiates. The small intestine has impaired motility for one to two days postoperatively, whereas the colon has impaired motility for two to three days on average [<a href="#rid87">87</a>]. Several animal studies have demonstrated prevention and treatment of postoperative adhesions with methods utilizing prokinetic agents or anatomically based visceral mobilization and manipulation to promote normal bowel motility and mobility [<a href="#rid88">88-90</a>]. Promoting return to normal bowel motility and early mobility remain areas of future inquiry for human research. Measures that promote postoperative bowel motility and reduce ileus are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/15155.html" rel="external">"Measures to prevent prolonged postoperative ileus"</a>.)</p><p class="headingAnchor" id="H1390229951"><span class="h2">Investigational agents</span><span class="headingEndMark"> — </span>There are multiple pharmaceutical targets being examined to limit peritoneal adhesion formation with promising preliminary evidence in animal-based studies. These include angiotensin receptor agonists, hypoxia-inducible factor inhibitors, N-acetyl-cysteine, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) [<a href="#rid91">91</a>], neurokinin-1 receptor antagonists, chymase inhibitors, sodium cromoglycate, <a class="drug drug_general" data-topicid="88424" href="/d/drug information/88424.html" rel="external">pirfenidone</a>, and selective small molecule activator protein-1. The theoretical mechanisms for adhesion prevention for most of these targets are reduced inflammation and increased fibrinolysis [<a href="#rid33">33</a>]. However, these studies are often done in animal models with few subjects; thus, more in vivo studies and human trials will need to be conducted prior to utilization [<a href="#rid33">33</a>].</p><p>Traditional medicine has also been employed in hope of postoperative adhesion prevention. <em>Punica granatum</em> L flower extract is traditionally used in ancient Persian medicine for its antimicrobial, antioxidant, and anti-inflammatory effects. A study done with 32 rat models taking <em>P. granatum</em> extract orally for eight days demonstrated a decrease in quantity and quality of adhesions [<a href="#rid92">92</a>].</p><p>Moving forward, the 2021 Global Expert Consensus Group has worked together to produce a consensus statement to guide future clinical research trials. All are in agreement that more studies need to be conducted to improve antiadhesion therapy and ultimately improve patient outcomes [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H355419621"><span class="h2">Ineffective and potentially harmful therapies</span><span class="headingEndMark"> — </span>A number of other agents have been applied in attempts to prevent postoperative peritoneal adhesions but are considered generally ineffective and possibly harmful. </p><p>Since adhesion formation involves an inflammatory reaction, systemic anti-inflammatory agents have been viewed as having potential value in efforts to prevent adhesion formation. A systematic review of randomized trials comparing the use of glucocorticoids or <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> versus no treatment for adhesion prevention after gynecologic surgery found no evidence for a beneficial effect of treatment [<a href="#rid94">94</a>], but the small number of studies and subjects precluded a confident conclusion. Although there is evidence from animal studies that <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a>, interleukin 10, and interleukin 4 have efficacy for reducing adhesion formation [<a href="#rid95">95-97</a>], there are no clinical trials of nonsteroidal anti-inflammatory drugs for this purpose involving humans.</p><p>Crystalloid solutions should not be expected to prevent adhesion formation, because of their short intraperitoneal time of residence, and this prediction is consistent with clinical observation [<a href="#rid98">98</a>]. The instillation of nonbarrier fluid into the peritoneal cavity at the conclusion of surgery is associated with numerous theoretical and practical concerns [<a href="#rid99">99-104</a>]. Fluid overload may potentially lead to pulmonary edema and may cause abdominal pain and dyspnea. Fluid may potentially leak through laparoscopic incisions, which may cause distress to the patient and require frequent bandage replacement. Extravasation to the vulvar region has been reported in up to 2 percent of patients receiving dextran 70 [<a href="#rid104">104</a>]. Excess intraperitoneal fluid also may reduce opsonization of foreign cells, impair host-cell phagocytosis, and lead to infectious complications. In one animal study, dextran significantly reduced adhesion formation but resulted in peritonitis rather than in abscesses as was observed with instillation of <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> [<a href="#rid105">105</a>].</p><p>However, it is possible that continuous lavage with crystalloid solutions may be beneficial, although further study is required. In one trial of laparoscopic myomectomy patients, postoperative peritoneal lavage with <a class="drug drug_general" data-topicid="108196" href="/d/drug information/108196.html" rel="external">Lactated Ringer</a> solution for 48 hours reduced adhesion formation assessed by second-look laparoscopy 8 to 10 weeks later [<a href="#rid106">106</a>]. The rates of postoperative complications and small bowel obstruction were not reported.</p><p>Other solutions instilled into the peritoneum to reduce adhesion formation have been evaluated and are ineffective. A systematic review found no significant benefit from the use of intraoperative irrigation or infusion of various drugs and liquids, including intraperitoneal steroids (one trial, 61 subjects), dextran (two trials, 210 subjects), or heparin (one trial, 63 subjects) [<a href="#rid94">94</a>]. Antibiotic solutions also are ineffective for preventing adhesions, and, in rats, irrigation of the abdominal cavity with <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> and <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> resulted in increased formation of peritoneal adhesions [<a href="#rid107">107</a>]. </p><p class="headingAnchor" id="H355417239"><span class="h1">EFFECTIVENESS OF PHYSICAL BARRIERS</span></p><p class="headingAnchor" id="H355417252"><span class="h2">Reducing adhesive obstruction</span><span class="headingEndMark"> — </span>Several of the barrier agents appear to be effective for reducing the incidence and extent of adhesions, but convincing effectiveness for reducing the incidence of adhesive bowel obstruction is available only for hyaluronic acid sheets [<a href="#rid1">1,52,108</a>].</p><p>A systematic review and meta-analysis identified nine trials [<a href="#rid46">46,52-55,109-113</a>] comparing hyaluronic acid sheets (Seprafilm) to no barrier [<a href="#rid1">1</a>]. Five studies compared the incidence of reoperations for adhesive small bowel obstruction; three trials were in patients having colorectal surgery, and the other two involved hepatic and gastric surgery. The use of hyaluronic acid sheets significantly reduced the risk for reoperation for adhesive small bowel obstruction, compared with no barrier, in patients having colorectal surgery (relative risk [RR] 0.49, 95% CI 0.28-0.88). </p><p>A separate review and meta-analysis [<a href="#rid43">43</a>] identified eight trials comparing Seprafilm to no barrier in 4203 patients [<a href="#rid47">47,49-55</a>]. Although the incidence of severe adhesions (grade 2 or 3) was significantly lower in the group receiving Seprafilm (odds ratio [OR] 0.45, 95% CI 0.22-0.93), the incidence of intestinal obstruction after abdominal surgery was not different.</p><p>In a systematic review of trials comparing <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> to no adhesion barrier or placebo, icodextrin significantly reduced the incidence of small bowel obstruction by any cause (RR 0.20, 95% CI 0.04-0.88), but the incidence of reoperation for adhesive small bowel obstruction was not different [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H355417259"><span class="h2">Improving fertility</span><span class="headingEndMark"> — </span>The effect of adhesion barriers (<a class="drug drug_general" data-topicid="10083" href="/d/drug information/10083.html" rel="external">oxidized regenerated cellulose</a> [ORC], expanded polytetrafluoroethylene [ePTFE], instillates) on rates of miscarriage or pregnancy in women following gynecologic surgery is unknown. Although many studies have examined surrogate endpoints such as adhesion or fertility scores, most have not studied the effect of adhesion barriers on conception, miscarriage, or live birth rates [<a href="#rid58">58,59,78,80,94,108,114,115</a>]. At present, there is no evidence for higher pregnancy or live birth rates with the use of adhesion barriers. </p><p>In one systematic review, no trials were identified reporting data on pregnancy rates for ORC, <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a>, or polyethylene glycol (PEG) [<a href="#rid1">1</a>]. In another that identified four trials, hyaluronic acid solutions had no significant effect on subsequent pregnancy rates [<a href="#rid80">80</a>]. </p><p>A review of five trials that compared antiadhesion barrier gels with another barrier gel, placebo, or no adjunctive therapy after hysteroscopic surgery included only one small study that reported pregnancy or live birth (but not miscarriage) rates; although the incidence of new adhesions was reduced, there was no difference in any of the more important clinical outcomes [<a href="#rid115">115</a>]. In a small pilot trial, the use of an antiadhesive gel post-salpingo-ovariolysis did not influence follicular development, as inferred from the results of the day 21 progesterone and folliculogram on days 10 to 12 three months postsurgery [<a href="#rid116">116</a>]. More well-designed and adequately powered randomized studies are needed to assess whether the use of any antiadhesion barriers can improve reproductive outcomes. </p><p>Given the absence of evidence that any antiadhesion agent can improve clinical outcomes, surgical adhesiolysis remains an important treatment option. Among infertile women with adnexal adhesions, pregnancy rates were lower in women with untreated adhesions compared with those who had adhesiolysis [<a href="#rid117">117</a>]. Pregnancy rates in treated women were 32 percent after 12 months and 45 percent after 24 months, compared with 11 and 16 percent, respectively, in control subjects. (See  <a class="medical medical_review" href="/d/html/5448.html" rel="external">"Female infertility: Treatments", section on 'Tubal factor infertility and adhesions'</a>.)</p><p class="headingAnchor" id="H355417266"><span class="h2">Lessening chronic pain</span><span class="headingEndMark"> — </span>Laparoscopic adhesiolysis as a therapy for chronic pain is controversial. Adhesiolysis for reducing chronic pain has been studied in two small trials following patients for up to one year with conflicting results [<a href="#rid118">118,119</a>]. In a small multicenter, randomized, double-blind trial with a 12 year follow-up, laparoscopic adhesiolysis was inferior to laparoscopy alone (control group) in chronic pain control and quality of life, and laparoscopy alone conveyed a powerful, long-term placebo effect [<a href="#rid120">120</a>]. A Cochrane review of four trials involving women with chronic pelvic pain showed uncertain benefit of adhesiolysis except for an improvement in the quality of life in terms of emotional wellbeing and social support [<a href="#rid121">121</a>].</p><p class="headingAnchor" id="H1186871471"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116755.html" rel="external">"Society guideline links: Bowel obstruction"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The adhesions that form in the abdomen after abdominal or pelvic surgery result from tissue trauma and subsequent healing and are a normal response of the peritoneal surfaces to surgical injury. Adhesion formation involves a complex interaction of many cell-secreted factors in areas of surgical trauma. The balance between fibrin deposition and degradation (ie, fibrinolysis) appears to be the critical factor in adhesion formation. (See <a class="local">'Incidence and burden'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentations</strong> – Although adhesion formation is integral to the healing process, adhesions can cause significant morbidity. Adhesions are the most common cause of bowel obstruction and should be suspected in any patient with a history of prior abdominal or pelvic surgery who presents with signs and symptoms of bowel obstruction. Other clinical consequences of adhesions include infertility and chronic abdominal pain. (See <a class="local">'Clinical presentations and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for adhesiolysis </strong>–<strong> </strong>Surgical lysis of adhesions may be indicated under the following clinical circumstances (see <a class="local">'Indications for adhesiolysis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop signs and symptoms of postoperative bowel obstruction that persists after conservative management</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For treatment of infertility and recurrent pregnancy loss</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measure for prevention of peritoneal adhesions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The first-line defense against adhesion formation is meticulous surgical technique. Although laparoscopy generally results in less tissue trauma than laparotomy, the incidence and severity of postoperative adhesions after laparoscopy is not necessarily lower than that after laparotomy. (See <a class="local">'Surgical techniques'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients at high risk for developing adhesions having laparotomy (eg, gynecologic surgery, repeat laparotomy), we suggest using a solid physical barrier such as Interceed (<a class="drug drug_general" data-topicid="10083" href="/d/drug information/10083.html" rel="external">oxidized regenerated cellulose</a>) for adhesion prevention, rather than a liquid barrier agent or no barrier (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Physical barriers'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients undergoing laparoscopic lysis of adhesions, we suggest the use of liquid barrier agents such as <a class="drug drug_general" data-topicid="8769" href="/d/drug information/8769.html" rel="external">icodextrin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Icodextrin solution'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest avoiding the use of nonbarrier intra-abdominal fluid solutions, antibiotics, and antithrombotic agents because they are ineffective and potentially harmful (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Ineffective and potentially harmful therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ten Broek RP, Stommel MW, Strik C, et al. Benefits and harms of adhesion barriers for abdominal surgery: a systematic review and meta-analysis. Lancet 2014; 383:48.</a></li><li><a class="nounderline abstract_t">Diamond MP, Freeman ML. Clinical implications of postsurgical adhesions. Hum Reprod Update 2001; 7:567.</a></li><li><a class="nounderline abstract_t">Davey AK, Maher PJ. Surgical adhesions: a timely update, a great challenge for the future. J Minim Invasive Gynecol 2007; 14:15.</a></li><li><a class="nounderline abstract_t">Schreinemacher MH, ten Broek RP, Bakkum EA, et al. Adhesion awareness: a national survey of surgeons. World J Surg 2010; 34:2805.</a></li><li><a class="nounderline abstract_t">Wilson MS. Practicalities and costs of adhesions. Colorectal Dis 2007; 9 Suppl 2:60.</a></li><li><a class="nounderline abstract_t">De Wilde RL, Brölmann H, Koninckx PR, et al. Prevention of adhesions in gynaecological surgery: the 2012 European field guideline. Gynecol Surg 2012; 9:365.</a></li><li><a class="nounderline abstract_t">Al-Took S, Platt R, Tulandi T. Adhesion-related small-bowel obstruction after gynecologic operations. Am J Obstet Gynecol 1999; 180:313.</a></li><li><a class="nounderline abstract_t">Ouaïssi M, Gaujoux S, Veyrie N, et al. Post-operative adhesions after digestive surgery: their incidence and prevention: review of the literature. J Visc Surg 2012; 149:e104.</a></li><li><a class="nounderline abstract_t">Barmparas G, Branco BC, Schnüriger B, et al. The incidence and risk factors of post-laparotomy adhesive small bowel obstruction. J Gastrointest Surg 2010; 14:1619.</a></li><li><a class="nounderline abstract_t">Lower AM, Hawthorn RJ, Ellis H, et al. The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study. BJOG 2000; 107:855.</a></li><li><a class="nounderline abstract_t">Lower AM, Hawthorn RJ, Clark D, et al. Adhesion-related readmissions following gynaecological laparoscopy or laparotomy in Scotland: an epidemiological study of 24 046 patients. Hum Reprod 2004; 19:1877.</a></li><li><a class="nounderline abstract_t">Ellis H, Moran BJ, Thompson JN, et al. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. Lancet 1999; 353:1476.</a></li><li><a class="nounderline abstract_t">Al-Sunaidi M, Tulandi T. Adhesion-related bowel obstruction after hysterectomy for benign conditions. Obstet Gynecol 2006; 108:1162.</a></li><li><a class="nounderline abstract_t">Schnüriger B, Barmparas G, Branco BC, et al. Prevention of postoperative peritoneal adhesions: a review of the literature. Am J Surg 2011; 201:111.</a></li><li><a class="nounderline abstract_t">van Goor H. Consequences and complications of peritoneal adhesions. Colorectal Dis 2007; 9 Suppl 2:25.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine, Society of Reproductive Surgeons. Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery. Fertil Steril 2007; 88:21.</a></li><li><a class="nounderline abstract_t">ten Broek RP, Schreinemacher MH, Jilesen AP, et al. Enterotomy risk in abdominal wall repair: a prospective study. Ann Surg 2012; 256:280.</a></li><li><a class="nounderline abstract_t">ten Broek RP, Strik C, Issa Y, et al. Adhesiolysis-related morbidity in abdominal surgery. Ann Surg 2013; 258:98.</a></li><li><a class="nounderline abstract_t">Van Der Krabben AA, Dijkstra FR, Nieuwenhuijzen M, et al. Morbidity and mortality of inadvertent enterotomy during adhesiotomy. Br J Surg 2000; 87:467.</a></li><li><a class="nounderline abstract_t">Ellis H. The clinical significance of adhesions: focus on intestinal obstruction. Eur J Surg Suppl 1997; :5.</a></li><li><a class="nounderline abstract_t">Sikirica V, Bapat B, Candrilli SD, et al. The inpatient burden of abdominal and gynecological adhesiolysis in the US. BMC Surg 2011; 11:13.</a></li><li><a class="nounderline abstract_t">Reed KL, Fruin AB, Bishop-Bartolomei KK, et al. Neurokinin-1 receptor and substance P messenger RNA levels increase during intraabdominal adhesion formation. J Surg Res 2002; 108:165.</a></li><li><a class="nounderline abstract_t">Brüggmann D, Tchartchian G, Wallwiener M, et al. Intra-abdominal adhesions: definition, origin, significance in surgical practice, and treatment options. Dtsch Arztebl Int 2010; 107:769.</a></li><li><a class="nounderline abstract_t">Hellebrekers BW, Kooistra T. Pathogenesis of postoperative adhesion formation. Br J Surg 2011; 98:1503.</a></li><li><a class="nounderline abstract_t">Ellis H. Medicolegal consequences of postoperative intra-abdominal adhesions. J R Soc Med 2001; 94:331.</a></li><li><a class="nounderline abstract_t">Cheong YC, Laird SM, Li TC, et al. Peritoneal healing and adhesion formation/reformation. Hum Reprod Update 2001; 7:556.</a></li><li><a class="nounderline abstract_t">Monk BJ, Berman ML, Montz FJ. Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention. Am J Obstet Gynecol 1994; 170:1396.</a></li><li><a class="nounderline abstract_t">Arung W, Meurisse M, Detry O. Pathophysiology and prevention of postoperative peritoneal adhesions. World J Gastroenterol 2011; 17:4545.</a></li><li><a class="nounderline abstract_t">Attard JA, MacLean AR. Adhesive small bowel obstruction: epidemiology, biology and prevention. Can J Surg 2007; 50:291.</a></li><li><a class="nounderline abstract_t">diZerega GS. Biochemical events in peritoneal tissue repair. Eur J Surg Suppl 1997; :10.</a></li><li><a class="nounderline abstract_t">Diamond MP, El-Hammady E, Wang R, et al. Regulation of expression of tissue plasminogen activator and plasminogen activator inhibitor-1 by dichloroacetic acid in human fibroblasts from normal peritoneum and adhesions. Am J Obstet Gynecol 2004; 190:926.</a></li><li><a class="nounderline abstract_t">Demco L. Pain mapping of adhesions. J Am Assoc Gynecol Laparosc 2004; 11:181.</a></li><li><a class="nounderline abstract_t">Fatehi Hassanabad A, Zarzycki AN, Jeon K, et al. Prevention of Post-Operative Adhesions: A Comprehensive Review of Present and Emerging Strategies. Biomolecules 2021; 11.</a></li><li><a class="nounderline abstract_t">Tulandi T, Hum HS, Gelfand MM. Closure of laparotomy incisions with or without peritoneal suturing and second-look laparoscopy. Am J Obstet Gynecol 1988; 158:536.</a></li><li><a class="nounderline abstract_t">Stricker B, Blanco J, Fox HE. The gynecologic contribution to intestinal obstruction in females. J Am Coll Surg 1994; 178:617.</a></li><li><a class="nounderline abstract_t">Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg 2012; 99:270.</a></li><li><a class="nounderline abstract_t">Burns EM, Currie A, Bottle A, et al. Minimal-access colorectal surgery is associated with fewer adhesion-related admissions than open surgery. Br J Surg 2013; 100:152.</a></li><li><a class="nounderline abstract_t">Keckstein J, Ulrich U, Sasse V, et al. Reduction of postoperative adhesion formation after laparoscopic ovarian cystectomy. Hum Reprod 1996; 11:579.</a></li><li><a class="nounderline abstract_t">Levrant SG, Bieber EJ, Barnes RB. Anterior abdominal wall adhesions after laparotomy or laparoscopy. J Am Assoc Gynecol Laparosc 1997; 4:353.</a></li><li><a class="nounderline abstract_t">Yesildaglar N, Koninckx PR. Adhesion formation in intubated rabbits increases with high insufflation pressure during endoscopic surgery. Hum Reprod 2000; 15:687.</a></li><li><a class="nounderline abstract_t">Krielen P, Stommel MWJ, Pargmae P, et al. Adhesion-related readmissions after open and laparoscopic surgery: a retrospective cohort study (SCAR update). Lancet 2020; 395:33.</a></li><li><a class="nounderline abstract_t">Ahmad G, O'Flynn H, Hindocha A, Watson A. Barrier agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev 2015; :CD000475.</a></li><li><a class="nounderline abstract_t">Zeng Q, Yu Z, You J, Zhang Q. Efficacy and safety of Seprafilm for preventing postoperative abdominal adhesion: systematic review and meta-analysis. World J Surg 2007; 31:2125.</a></li><li><a class="nounderline abstract_t">Moreira H Jr, Wexner SD, Yamaguchi T, et al. Use of bioresorbable membrane (sodium hyaluronate + carboxymethylcellulose) after controlled bowel injuries in a rabbit model. Dis Colon Rectum 2000; 43:182.</a></li><li><a class="nounderline abstract_t">Tzianabos AO, Cisneros RL, Gershkovich J, et al. Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection. Arch Surg 1999; 134:1254.</a></li><li><a class="nounderline abstract_t">Beck DE. The role of Seprafilm bioresorbable membrane in adhesion prevention. Eur J Surg Suppl 1997; :49.</a></li><li><a class="nounderline abstract_t">Beck DE, Cohen Z, Fleshman JW, et al. A prospective, randomized, multicenter, controlled study of the safety of Seprafilm adhesion barrier in abdominopelvic surgery of the intestine. Dis Colon Rectum 2003; 46:1310.</a></li><li><a class="nounderline abstract_t">Wada Y, Takahashi H, Matsui H, et al. Adhesion barriers and intraperitoneal or uterine infections after cesarean section: A retrospective cohort study. Surgery 2022; 172:1722.</a></li><li><a class="nounderline abstract_t">Vrijland WW, Tseng LN, Eijkman HJ, et al. Fewer intraperitoneal adhesions with use of hyaluronic acid-carboxymethylcellulose membrane: a randomized clinical trial. Ann Surg 2002; 235:193.</a></li><li><a class="nounderline abstract_t">Cohen Z, Senagore AJ, Dayton MT, et al. Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis Colon Rectum 2005; 48:1130.</a></li><li><a class="nounderline abstract_t">Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg 1996; 183:297.</a></li><li><a class="nounderline abstract_t">Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm adhesion barrier after intestinal resection. Dis Colon Rectum 2006; 49:1.</a></li><li><a class="nounderline abstract_t">Kusunoki M, Ikeuchi H, Yanagi H, et al. Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Surg Today 2005; 35:940.</a></li><li><a class="nounderline abstract_t">Salum M, Wexner SD, Nogueras JJ, et al. Does sodium hyaluronate- and carboxymethylcellulose-based bioresorbable membrane (Seprafilm) decrease operative time for loop ileostomy closure? Tech Coloproctol 2006; 10:187.</a></li><li><a class="nounderline abstract_t">Inoue M, Uchida K, Miki C, Kusunoki M. Efficacy of Seprafilm for reducing reoperative risk in pediatric surgical patients undergoing abdominal surgery. J Pediatr Surg 2005; 40:1301.</a></li><li><a class="nounderline abstract_t">Guo Y, Zhu Q, Chen S, et al. Effect of sodium hyaluronate-arboxycellulose membrane (Seprafilm®) on postoperative small bowel obstruction: A meta-analysis. Surgery 2021; 169:1333.</a></li><li><a class="nounderline abstract_t">Dimitrijevich SD, Tatarko M, Gracy RW, et al. In vivo degradation of oxidized, regenerated cellulose. Carbohydr Res 1990; 198:331.</a></li><li><a class="nounderline abstract_t">Greenblatt EM, Casper RF. Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fertil Steril 1993; 60:766.</a></li><li><a class="nounderline abstract_t">The efficacy of Interceed(TC7)* for prevention of reformation of postoperative adhesions on ovaries, fallopian tubes, and fimbriae in microsurgical operations for fertility: a multicenter study. Nordic Adhesion Prevention Study Group. Fertil Steril 1995; 63:709.</a></li><li><a class="nounderline abstract_t">Tinelli A, Malvasi A, Guido M, et al. Adhesion formation after intracapsular myomectomy with or without adhesion barrier. Fertil Steril 2011; 95:1780.</a></li><li><a class="nounderline abstract_t">Azziz R. Microsurgery alone or with INTERCEED Absorbable Adhesion Barrier for pelvic sidewall adhesion re-formation. The INTERCEED (TC7) Adhesion Barrier Study Group II. Surg Gynecol Obstet 1993; 177:135.</a></li><li><a class="nounderline abstract_t">Franklin RR. Reduction of ovarian adhesions by the use of Interceed. Ovarian Adhesion Study Group. Obstet Gynecol 1995; 86:335.</a></li><li><a class="nounderline abstract_t">Li TC, Cooke ID. The value of an absorbable adhesion barrier, Interceed, in the prevention of adhesion reformation following microsurgical adhesiolysis. Br J Obstet Gynaecol 1994; 101:335.</a></li><li><a class="nounderline abstract_t">Saravelos H, Li TC. Post-operative adhesions after laparoscopic electrosurgical treatment for polycystic ovarian syndrome with the application of Interceed to one ovary: a prospective randomized controlled study. Hum Reprod 1996; 11:992.</a></li><li><a class="nounderline abstract_t">Sekiba K. Use of Interceed(TC7) absorbable adhesion barrier to reduce postoperative adhesion reformation in infertility and endometriosis surgery. The Obstetrics and Gynecology Adhesion Prevention Committee. Obstet Gynecol 1992; 79:518.</a></li><li><a class="nounderline abstract_t">Mais V, Ajossa S, Piras B, et al. Prevention of de-novo adhesion formation after laparoscopic myomectomy: a randomized trial to evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier. Hum Reprod 1995; 10:3133.</a></li><li><a class="nounderline abstract_t">Mais V, Ajossa S, Marongiu D, et al. Reduction of adhesion reformation after laparoscopic endometriosis surgery: a randomized trial with an oxidized regenerated cellulose absorbable barrier. Obstet Gynecol 1995; 86:512.</a></li><li><a class="nounderline abstract_t">Wiseman DM, Gottlick-Iarkowski L, Kamp L. Effect of different barriers of oxidized regenerated cellulose (ORC) on cecal and sidewall adhesions in the presence and absence of bleeding. J Invest Surg 1999; 12:141.</a></li><li><a class="nounderline abstract_t">An expanded polytetrafluoroethylene barrier (Gore-Tex Surgical Membrane) reduces post-myomectomy adhesion formation. The Myomectomy Adhesion Multicenter Study Group. Fertil Steril 1995; 63:491.</a></li><li><a class="nounderline abstract_t">Haney AF, Hesla J, Hurst BS, et al. Expanded polytetrafluoroethylene (Gore-Tex Surgical Membrane) is superior to oxidized regenerated cellulose (Interceed TC7+) in preventing adhesions. Fertil Steril 1995; 63:1021.</a></li><li><a class="nounderline abstract_t">Mettler L, Audebert A, Lehmann-Willenbrock E, et al. A randomized, prospective, controlled, multicenter clinical trial of a sprayable, site-specific adhesion barrier system in patients undergoing myomectomy. Fertil Steril 2004; 82:398.</a></li><li><a class="nounderline abstract_t">Tjandra JJ, Chan MK. A sprayable hydrogel adhesion barrier facilitates closure of defunctioning loop ileostomy: a randomized trial. Dis Colon Rectum 2008; 51:956.</a></li><li><a class="nounderline abstract_t">Mettler L, Hucke J, Bojahr B, et al. A safety and efficacy study of a resorbable hydrogel for reduction of post-operative adhesions following myomectomy. Hum Reprod 2008; 23:1093.</a></li><li><a class="nounderline abstract_t">Johns DA, Ferland R, Dunn R. Initial feasibility study of a sprayable hydrogel adhesion barrier system in patients undergoing laparoscopic ovarian surgery. J Am Assoc Gynecol Laparosc 2003; 10:334.</a></li><li><a class="nounderline abstract_t">Banasiewicz T, Horbacka K, Karoń J, et al. Preliminary study with SprayShield™ Adhesion Barrier System in the prevention of abdominal adhesions. Wideochir Inne Tech Maloinwazyjne 2013; 8:301.</a></li><li><a class="nounderline abstract_t">Ten Broek RP, Kok-Krant N, Verhoeve HR, et al. Efficacy of polyethylene glycol adhesion barrier after gynecological laparoscopic surgery: Results of a randomized controlled pilot study. Gynecol Surg 2012; 9:29.</a></li><li><a class="nounderline abstract_t">Tchartchian G, Hackethal A, Herrmann A, et al. Evaluation of SprayShield™ Adhesion Barrier in a single center: randomized controlled study in 15 women undergoing reconstructive surgery after laparoscopic myomectomy. Arch Gynecol Obstet 2014; 290:697.</a></li><li><a class="nounderline abstract_t">Brown CB, Luciano AA, Martin D, et al. Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study. Fertil Steril 2007; 88:1413.</a></li><li><a class="nounderline abstract_t">Tang CL, Jayne DG, Seow-Choen F, et al. A randomized controlled trial of 0.5% ferric hyaluronate gel (Intergel) in the prevention of adhesions following abdominal surgery. Ann Surg 2006; 243:449.</a></li><li><a class="nounderline abstract_t">Metwally M, Gorvy D, Watson A, Li TC. Hyaluronic acid fluid agents for the prevention of adhesions after fertility-preserving gynecological surgery: a meta-analysis of randomized controlled trials. Fertil Steril 2007; 87:1139.</a></li><li><a class="nounderline abstract_t">Mais V, Cirronis MG, Peiretti M, et al. Efficacy of auto-crosslinked hyaluronan gel for adhesion prevention in laparoscopy and hysteroscopy: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2012; 160:1.</a></li><li><a class="nounderline abstract_t">Johns DB, Keyport GM, Hoehler F, et al. Reduction of postsurgical adhesions with Intergel adhesion prevention solution: a multicenter study of safety and efficacy after conservative gynecologic surgery. Fertil Steril 2001; 76:595.</a></li><li><a class="nounderline abstract_t">Lundorff P, van Geldorp H, Tronstad SE, et al. Reduction of post-surgical adhesions with ferric hyaluronate gel: a European study. Hum Reprod 2001; 16:1982.</a></li><li><a class="nounderline abstract_t">Pellicano M, Bramante S, Cirillo D, et al. Effectiveness of autocrosslinked hyaluronic acid gel after laparoscopic myomectomy in infertile patients: a prospective, randomized, controlled study. Fertil Steril 2003; 80:441.</a></li><li><a class="nounderline abstract_t">Diamond MP. Reduction of de novo postsurgical adhesions by intraoperative precoating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicenter study. The Sepracoat Adhesion Study Group. Fertil Steril 1998; 69:1067.</a></li><li><a class="nounderline abstract_t">Berdah SV, Mariette C, Denet C, et al. A multicentre, randomised, controlled trial to assess the safety, ease of use, and reliability of hyaluronic acid/carboxymethylcellulose powder adhesion barrier versus no barrier in colorectal laparoscopic surgery. Trials 2014; 15:413.</a></li><li><a class="nounderline abstract_t">Artinyan A, Nunoo-Mensah JW, Balasubramaniam S, et al. Prolonged postoperative ileus-definition, risk factors, and predictors after surgery. World J Surg 2008; 32:1495.</a></li><li><a class="nounderline abstract_t">Bove GM, Chapelle SL, Hanlon KE, et al. Attenuation of postoperative adhesions using a modeled manual therapy. PLoS One 2017; 12:e0178407.</a></li><li><a class="nounderline abstract_t">Bove GM, Chapelle SL. Visceral mobilization can lyse and prevent peritoneal adhesions in a rat model. J Bodyw Mov Ther 2012; 16:76.</a></li><li><a class="nounderline abstract_t">Springall RG, Spitz L. The prevention of post-operative adhesions using a gastrointestinal prokinetic agent. J Pediatr Surg 1989; 24:530.</a></li><li><a class="nounderline abstract_t">Scott FI, Vajravelu RK, Mamtani R, et al. Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction. JAMA Netw Open 2021; 4:e2036315.</a></li><li><a class="nounderline abstract_t">Mahmoudieh M, Keleidari B, Nasr Esfahani F, et al. The effect of Punica granatum L. flower extract on post-surgical peritoneal adhesions in a rat model. Eur J Obstet Gynecol Reprod Biol 2020; 246:113.</a></li><li><a class="nounderline abstract_t">De Wilde RL, Devassy R, Broek RPGT, et al. The Future of Adhesion Prophylaxis Trials in Abdominal Surgery: An Expert Global Consensus. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Metwally M, Watson A, Lilford R, Vandekerckhove P. Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev 2006; :CD001298.</a></li><li><a class="nounderline abstract_t">LeGrand EK, Rodgers KE, Girgis W, et al. Comparative efficacy of nonsteroidal anti-inflammatory drugs and anti-thromboxane agents in a rabbit adhesion-prevention model. J Invest Surg 1995; 8:187.</a></li><li><a class="nounderline abstract_t">Montz FJ, Monk BJ, Lacy SM, Fowler JM. Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model. Gynecol Oncol 1993; 48:76.</a></li><li><a class="nounderline abstract_t">Holschneider CH, Nejad F, Montz FJ. Immunomodulation with interleukin-10 and interleukin-4 compared with ketorolac tromethamine for prevention of postoperative adhesions in a murine model. Fertil Steril 1999; 71:67.</a></li><li><a class="nounderline abstract_t">diZerega GS. Contemporary adhesion prevention. Fertil Steril 1994; 61:219.</a></li><li><a class="nounderline abstract_t">Ricaurte E, Hilgers TW. Safety of intraperitoneal 32% dextran 70 as an antiadhesion adjuvant. J Reprod Med 1989; 34:535.</a></li><li><a class="nounderline abstract_t">Sites CK, Jensen BA, Glock JL, et al. Transvaginal ultrasonographic assessment of Hyskon or lactated Ringer's solution instillation after laparoscopy: randomized, controlled study. J Ultrasound Med 1997; 16:195.</a></li><li><a class="nounderline abstract_t">Rose BI, MacNeill C, Larrain R, Kopreski MM. Abdominal instillation of high-molecular-weight dextran or lactated Ringer's solution after laparoscopic surgery. A randomized comparison of the effect on weight change. J Reprod Med 1991; 36:537.</a></li><li><a class="nounderline abstract_t">Tulandi T, Hilton J. Effect of intraperitoneal 32% dextran 70 on blood coagulation and serum electrolytes. J Reprod Med 1985; 30:431.</a></li><li><a class="nounderline abstract_t">Weinans MJ, Kauer FM, Klompmaker IJ, Wijma J. Transient liver function disturbances after the intraperitoneal use of 32% dextran 70 as adhesion prophylaxis in infertility surgery. Fertil Steril 1990; 53:159.</a></li><li><a class="nounderline abstract_t">Tulandi T. Transient edema after intraperitoneal instillation of 32% dextran 70. A report of five cases. J Reprod Med 1987; 32:472.</a></li><li><a class="nounderline abstract_t">Fabri PJ, Ellison EC, Anderson ED, Kudsk KA. High molecular weight dextran--effect on adhesion formation and peritonitis in rats. Surgery 1983; 94:336.</a></li><li><a class="nounderline abstract_t">Abu-Elhasan AM, Abdellah MS, Hamed HO. Safety and efficacy of postoperative continuous intra-peritoneal wash with lactated Ringer's for minimizing post-myomectomy pelvic adhesions: a pilot clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 183:78.</a></li><li><a class="nounderline abstract_t">Rappaport WD, Holcomb M, Valente J, Chvapil M. Antibiotic irrigation and the formation of intraabdominal adhesions. Am J Surg 1989; 158:435.</a></li><li><a class="nounderline abstract_t">Farquhar C, Vandekerckhove P, Watson A, et al. Barrier agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev 2000; :CD000475.</a></li><li><a class="nounderline abstract_t">Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril 1996; 66:904.</a></li><li><a class="nounderline abstract_t">Hayashi S, Takayama T, Masuda H, et al. Bioresorbable membrane to reduce postoperative small bowel obstruction in patients with gastric cancer: a randomized clinical trial. Ann Surg 2008; 247:766.</a></li><li><a class="nounderline abstract_t">Dupré A, Lefranc A, Buc E, et al. Use of bioresorbable membranes to reduce abdominal and perihepatic adhesions in 2-stage hepatectomy of liver metastases from colorectal cancer: results of a prospective, randomized controlled phase II trial. Ann Surg 2013; 258:30.</a></li><li><a class="nounderline abstract_t">Park CM, Lee WY, Cho YB, et al. Sodium hyaluronate-based bioresorbable membrane (Seprafilm) reduced early postoperative intestinal obstruction after lower abdominal surgery for colorectal cancer: the preliminary report. Int J Colorectal Dis 2009; 24:305.</a></li><li><a class="nounderline abstract_t">van der Wal JB, Iordens GI, Vrijland WW, et al. Adhesion prevention during laparotomy: long-term follow-up of a randomized clinical trial. Ann Surg 2011; 253:1118.</a></li><li><a class="nounderline abstract_t">Ahmad G, Mackie FL, Iles DA, et al. Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev 2014; :CD001298.</a></li><li><a class="nounderline abstract_t">Bosteels J, Weyers S, Mol BW, D'Hooghe T. Anti-adhesion barrier gels following operative hysteroscopy for treating female infertility: a systematic review and meta-analysis. Gynecol Surg 2014; 11:113.</a></li><li><a class="nounderline abstract_t">Cheong Y, Bailey S, Forbes J. Randomized Controlled Trial of Hyalobarrier® Versus No Hyalobarrier® on the Ovulatory Status of Women with Periovarian Adhesions: A Pilot Study. Adv Ther 2017; 34:199.</a></li><li><a class="nounderline abstract_t">Tulandi T, Collins JA, Burrows E, et al. Treatment-dependent and treatment-independent pregnancy among women with periadnexal adhesions. Am J Obstet Gynecol 1990; 162:354.</a></li><li><a class="nounderline abstract_t">Swank DJ, Swank-Bordewijk SC, Hop WC, et al. Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-centre trial. Lancet 2003; 361:1247.</a></li><li><a class="nounderline abstract_t">Keltz MD, Gera PS, Olive DL. Prospective randomized trial of right-sided paracolic adhesiolysis for chronic pelvic pain. JSLS 2006; 10:443.</a></li><li><a class="nounderline abstract_t">Molegraaf MJ, Torensma B, Lange CP, et al. Twelve-year outcomes of laparoscopic adhesiolysis in patients with chronic abdominal pain: A randomized clinical trial. Surgery 2017; 161:415.</a></li><li><a class="nounderline abstract_t">Leonardi M, Armour M, Gibbons T, et al. Surgical interventions for the management of chronic pelvic pain in women. Cochrane Database Syst Rev 2021; 12:CD008212.</a></li></ol></div><div id="topicVersionRevision">Topic 2891 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075279" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Benefits and harms of adhesion barriers for abdominal surgery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11727865" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical implications of postsurgical adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218224" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgical adhesions: a timely update, a great challenge for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20814678" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adhesion awareness: a national survey of surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17824972" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Practicalities and costs of adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23144639" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention of adhesions in gynaecological surgery: the 2012 European field guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988792" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adhesion-related small-bowel obstruction after gynecologic operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22261580" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Post-operative adhesions after digestive surgery: their incidence and prevention: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20352368" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The incidence and risk factors of post-laparotomy adhesive small bowel obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10901556" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178659" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adhesion-related readmissions following gynaecological laparoscopy or laparotomy in Scotland: an epidemiological study of 24 046 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232313" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17077238" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adhesion-related bowel obstruction after hysterectomy for benign conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20817145" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevention of postoperative peritoneal adhesions: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17824967" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Consequences and complications of peritoneal adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613300" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22791104" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Enterotomy risk in abdominal wall repair: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013804" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Adhesiolysis-related morbidity in abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10759744" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Morbidity and mortality of inadvertent enterotomy during adhesiotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076446" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The clinical significance of adhesions: focus on intestinal obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658255" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The inpatient burden of abdominal and gynecological adhesiolysis in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12443729" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neurokinin-1 receptor and substance P messenger RNA levels increase during intraabdominal adhesion formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21116396" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intra-abdominal adhesions: definition, origin, significance in surgical practice, and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21877324" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pathogenesis of postoperative adhesion formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11418701" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Medicolegal consequences of postoperative intra-abdominal adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11727864" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Peritoneal healing and adhesion formation/reformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178880" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147959" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pathophysiology and prevention of postoperative peritoneal adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897517" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Adhesive small bowel obstruction: epidemiology, biology and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076447" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Biochemical events in peritoneal tissue repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15118614" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Regulation of expression of tissue plasminogen activator and plasminogen activator inhibitor-1 by dichloroacetic acid in human fibroblasts from normal peritoneum and adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15200771" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pain mapping of adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34356652" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevention of Post-Operative Adhesions: A Comprehensive Review of Present and Emerging Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2964783" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Closure of laparotomy incisions with or without peritoneal suturing and second-look laparoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8193757" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The gynecologic contribution to intestinal obstruction in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22095139" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23148018" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Minimal-access colorectal surgery is associated with fewer adhesion-related admissions than open surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671270" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reduction of postoperative adhesion formation after laparoscopic ovarian cystectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154785" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Anterior abdominal wall adhesions after laparotomy or laparoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686220" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adhesion formation in intubated rabbits increases with high insufflation pressure during endoscopic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31908284" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adhesion-related readmissions after open and laparoscopic surgery: a retrospective cohort study (SCAR update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25924805" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Barrier agents for adhesion prevention after gynaecological surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899250" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of Seprafilm for preventing postoperative abdominal adhesion: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10696891" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of bioresorbable membrane (sodium hyaluronate + carboxymethylcellulose) after controlled bowel injuries in a rabbit model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555642" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9076452" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The role of Seprafilm bioresorbable membrane in adhesion prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14530667" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A prospective, randomized, multicenter, controlled study of the safety of Seprafilm adhesion barrier in abdominopelvic surgery of the intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36210187" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adhesion barriers and intraperitoneal or uterine infections after cesarean section: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807358" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Fewer intraperitoneal adhesions with use of hyaluronic acid-carboxymethylcellulose membrane: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15868230" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8843257" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320005" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reduction in adhesive small-bowel obstruction by Seprafilm adhesion barrier after intestinal resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249848" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969618" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Does sodium hyaluronate- and carboxymethylcellulose-based bioresorbable membrane (Seprafilm) decrease operative time for loop ileostomy closure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080936" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of Seprafilm for reducing reoperative risk in pediatric surgical patients undergoing abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33461779" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of sodium hyaluronate-arboxycellulose membrane (Seprafilm®) on postoperative small bowel obstruction: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2379193" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : In vivo degradation of oxidized, regenerated cellulose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8224258" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7890052" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The efficacy of Interceed(TC7)* for prevention of reformation of postoperative adhesions on ovaries, fallopian tubes, and fimbriae in microsurgical operations for fertility: a multicenter study. Nordic Adhesion Prevention Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21256483" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adhesion formation after intracapsular myomectomy with or without adhesion barrier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8342092" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Microsurgery alone or with INTERCEED Absorbable Adhesion Barrier for pelvic sidewall adhesion re-formation. The INTERCEED (TC7) Adhesion Barrier Study Group II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7651638" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Reduction of ovarian adhesions by the use of Interceed. Ovarian Adhesion Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8199081" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The value of an absorbable adhesion barrier, Interceed, in the prevention of adhesion reformation following microsurgical adhesiolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8671376" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Post-operative adhesions after laparoscopic electrosurgical treatment for polycystic ovarian syndrome with the application of Interceed to one ovary: a prospective randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1553169" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Use of Interceed(TC7) absorbable adhesion barrier to reduce postoperative adhesion reformation in infertility and endometriosis surgery. The Obstetrics and Gynecology Adhesion Prevention Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822429" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prevention of de-novo adhesion formation after laparoscopic myomectomy: a randomized trial to evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675371" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Reduction of adhesion reformation after laparoscopic endometriosis surgery: a randomized trial with an oxidized regenerated cellulose absorbable barrier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421515" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of different barriers of oxidized regenerated cellulose (ORC) on cecal and sidewall adhesions in the presence and absence of bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7851575" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : An expanded polytetrafluoroethylene barrier (Gore-Tex Surgical Membrane) reduces post-myomectomy adhesion formation. The Myomectomy Adhesion Multicenter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7720911" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Expanded polytetrafluoroethylene (Gore-Tex Surgical Membrane) is superior to oxidized regenerated cellulose (Interceed TC7+) in preventing adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302290" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A randomized, prospective, controlled, multicenter clinical trial of a sprayable, site-specific adhesion barrier system in patients undergoing myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18219530" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A sprayable hydrogel adhesion barrier facilitates closure of defunctioning loop ileostomy: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346996" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A safety and efficacy study of a resorbable hydrogel for reduction of post-operative adhesions following myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567807" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Initial feasibility study of a sprayable hydrogel adhesion barrier system in patients undergoing laparoscopic ovarian surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24501599" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Preliminary study with SprayShield™Adhesion Barrier System in the prevention of abdominal adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22408577" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy of polyethylene glycol adhesion barrier after gynecological laparoscopic surgery: Results of a randomized controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781718" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Evaluation of SprayShield™Adhesion Barrier in a single center: randomized controlled study in 15 women undergoing reconstructive surgery after laparoscopic myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383643" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16552194" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A randomized controlled trial of 0.5% ferric hyaluronate gel (Intergel) in the prevention of adhesions following abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17478173" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hyaluronic acid fluid agents for the prevention of adhesions after fertility-preserving gynecological surgery: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21945572" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Efficacy of auto-crosslinked hyaluronan gel for adhesion prevention in laparoscopy and hysteroscopy: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11532487" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reduction of postsurgical adhesions with Intergel adhesion prevention solution: a multicenter study of safety and efficacy after conservative gynecologic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527909" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Reduction of post-surgical adhesions with ferric hyaluronate gel: a European study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12909511" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effectiveness of autocrosslinked hyaluronic acid gel after laparoscopic myomectomy in infertile patients: a prospective, randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9627294" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Reduction of de novo postsurgical adhesions by intraoperative precoating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicenter study. The Sepracoat Adhesion Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25348087" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A multicentre, randomised, controlled trial to assess the safety, ease of use, and reliability of hyaluronic acid/carboxymethylcellulose powder adhesion barrier versus no barrier in colorectal laparoscopic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305994" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prolonged postoperative ileus-definition, risk factors, and predictors after surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28574997" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Attenuation of postoperative adhesions using a modeled manual therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22196431" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Visceral mobilization can lyse and prevent peritoneal adhesions in a rat model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2738817" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The prevention of post-operative adhesions using a gastrointestinal prokinetic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33533930" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Association Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32004879" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The effect of Punica granatum L. flower extract on post-surgical peritoneal adhesions in a rat model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35329802" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The Future of Adhesion Prophylaxis Trials in Abdominal Surgery: An Expert Global Consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625541" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Fluid and pharmacological agents for adhesion prevention after gynaecological surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7547726" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Comparative efficacy of nonsteroidal anti-inflammatory drugs and anti-thromboxane agents in a rabbit adhesion-prevention model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8423025" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9935118" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Immunomodulation with interleukin-10 and interleukin-4 compared with ketorolac tromethamine for prevention of postoperative adhesions in a murine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299773" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Contemporary adhesion prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2478706" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Safety of intraperitoneal 32% dextran 70 as an antiadhesion adjuvant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166816" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Transvaginal ultrasonographic assessment of Hyskon or lactated Ringer's solution instillation after laparoscopy: randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1719197" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Abdominal instillation of high-molecular-weight dextran or lactated Ringer's solution after laparoscopic surgery. A randomized comparison of the effect on weight change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2409278" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of intraperitoneal 32% dextran 70 on blood coagulation and serum electrolytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688535" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Transient liver function disturbances after the intraperitoneal use of 32% dextran 70 as adhesion prophylaxis in infertility surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2441040" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Transient edema after intraperitoneal instillation of 32% dextran 70. A report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6192511" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : High molecular weight dextran--effect on adhesion formation and peritonitis in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25461357" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Safety and efficacy of postoperative continuous intra-peritoneal wash with lactated Ringer's for minimizing post-myomectomy pelvic adhesions: a pilot clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2817225" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Antibiotic irrigation and the formation of intraabdominal adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796548" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Barrier agents for preventing adhesions after surgery for subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941053" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18438113" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Bioresorbable membrane to reduce postoperative small bowel obstruction in patients with gastric cancer: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426344" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Use of bioresorbable membranes to reduce abdominal and perihepatic adhesions in 2-stage hepatectomy of liver metastases from colorectal cancer: results of a prospective, randomized controlled phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18953549" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Sodium hyaluronate-based bioresorbable membrane (Seprafilm) reduced early postoperative intestinal obstruction after lower abdominal surgery for colorectal cancer: the preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502860" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Adhesion prevention during laparotomy: long-term follow-up of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25005450" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Fluid and pharmacological agents for adhesion prevention after gynaecological surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795547" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Anti-adhesion barrier gels following operative hysteroscopy for treating female infertility: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27900662" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Randomized Controlled Trial of Hyalobarrier®Versus No Hyalobarrier®on the Ovulatory Status of Women with Periovarian Adhesions: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2309813" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Treatment-dependent and treatment-independent pregnancy among women with periadnexal adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12699951" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-centre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575754" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prospective randomized trial of right-sided paracolic adhesiolysis for chronic pelvic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27866713" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Twelve-year outcomes of laparoscopic adhesiolysis in patients with chronic abdominal pain: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34923620" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Surgical interventions for the management of chronic pelvic pain in women.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
